骆驼 FGF21 蛋白增强 FGF21 信号转导及其靶向化合物筛选

IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY Current pharmaceutical design Pub Date : 2024-09-30 DOI:10.2174/0113816128332755240912041051
Yuan Gao, Fang Yong, Wangye Ji, Lili Zhang, Jibao Hou, Ruilin Ma, Shuqin Zhao, Huizhen Ge, Xiaoyu Wu
{"title":"骆驼 FGF21 蛋白增强 FGF21 信号转导及其靶向化合物筛选","authors":"Yuan Gao, Fang Yong, Wangye Ji, Lili Zhang, Jibao Hou, Ruilin Ma, Shuqin Zhao, Huizhen Ge, Xiaoyu Wu","doi":"10.2174/0113816128332755240912041051","DOIUrl":null,"url":null,"abstract":"<p><p>The article has been withdrawn at the request of the author.</p><p><p>Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.</p><p><p>The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php</p><p><strong>Bentham science disclaimer: </strong>It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously\nsubmitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be\nreported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article\nfor publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or\nfabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to\nthe publishers if and when the article is accepted for publication.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Withdrawn: Camel FGF21 Protein Enhances FGF21 Signaling and its Targeted Compounds Screening\",\"authors\":\"Yuan Gao, Fang Yong, Wangye Ji, Lili Zhang, Jibao Hou, Ruilin Ma, Shuqin Zhao, Huizhen Ge, Xiaoyu Wu\",\"doi\":\"10.2174/0113816128332755240912041051\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The article has been withdrawn at the request of the author.</p><p><p>Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.</p><p><p>The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php</p><p><strong>Bentham science disclaimer: </strong>It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously\\nsubmitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be\\nreported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article\\nfor publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or\\nfabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to\\nthe publishers if and when the article is accepted for publication.</p>\",\"PeriodicalId\":10845,\"journal\":{\"name\":\"Current pharmaceutical design\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current pharmaceutical design\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0113816128332755240912041051\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128332755240912041051","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

简介成纤维细胞生长因子 21 (FGF21) 作为一种新型葡萄糖和脂质代谢调节剂,已成为治疗代谢性疾病的一个很有前景的靶点。骆驼是适应干旱和半干旱沙漠气候的特有物种,在调节脂质储备和利用方面表现出卓越的能力:方法:本研究通过序列分析和 FGF21 信号下游标记物的检测发现,与人和小鼠相比,骆驼 FGF21 对下游信号转导具有更强的调控作用。利用 CavityPlus 在线平台预测发现,FGF21 蛋白有一个潜在的药物结合口袋。利用加州大学旧金山分校的 DOCK6 程序进行分子对接,筛选出了四种靶向 FGF21 蛋白的小化合物:间苯二酚单乙酸酯、托吡司琼、尼利德林和斯奇潘托:结果:四种小化合物的抑制浓度 50%(IC50)值由 MTT 试验测定,并通过 GraphPad Prism 软件进行模拟。生物效应测试表明,这四种化合物参与了 FGF21 信号通路的调控,是 FGF21 信号转导的激动剂。而化合物与蛋白质共处理的阻断实验表明,这四种小化合物并不能抑制 FGF21 诱导的通路激活。甚至,间苯二酚单乙酸酯和斯奇潘托还能协同激活 FGF21 蛋白的下游信号通路:本研究为开发基于 FGF21 蛋白修饰的治疗策略提供了新思路,并探索了基于化合物-蛋白组合的新型疾病治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Withdrawn: Camel FGF21 Protein Enhances FGF21 Signaling and its Targeted Compounds Screening

The article has been withdrawn at the request of the author.

Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.

The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php

Bentham science disclaimer: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
302
审稿时长
2 months
期刊介绍: Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
期刊最新文献
Screening of Natural Compounds as Inhibitor of Mpro SARS-CoV-2 Protein; A Molecular Dynamics Approach. The Rise of FLiRT Variants in the COVID-19 Pandemic: What We Know So Far. Therapeutic Potential of Neutralizing Monoclonal Antibodies (nMAbs) against SARS-CoV-2 Omicron Variant. Co-loading Radio-photosensitizer Agents on Polymer and Lipid-based Nanocarriers for Radio-photodynamic Therapy Purposes: Review. Screening of Optimal Phytoconstituents through in silico Docking, Toxicity, Pharmacokinetic, and Molecular Dynamics Approach for Fighting against Polycystic Ovarian Syndrome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1